Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Julphar
Citi
Novartis
Harvard Business School
Healthtrust
Express Scripts
Fuji
Daiichi Sankyo
Accenture
Mallinckrodt

Generated: January 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,271,968

« Back to Dashboard

Which drugs does patent 9,271,968 protect, and when does it expire?

Patent 9,271,968 protects XIFAXAN and is included in two NDAs.

This patent has thirty patent family members in twenty-six countries.
Summary for Patent: 9,271,968
Title:Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
Abstract: Crystalline polymorphous forms of the rifaximin (INN) antibiotic named rifaximin .delta. and rifaximin .epsilon. useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.
Inventor(s): Viscomi; Giuseppe Claudio (Sasso Marconi, IT), Campana; Manuela (Bologna, IT), Confortini; Donatella (Calderara di Reno, IT), Barbanti; Maria (Bologna, IT), Braga; Dario (Bologna, IT)
Assignee: ALFA WASSERMANN S.P.A. (IT)
Application Number:14/262,612
Patent Claim Types:
see list of patent claims
Composition; Formulation; Dosage form;

Drugs Protected by US Patent 9,271,968

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Salix Pharms XIFAXAN rifaximin TABLET;ORAL 021361-001 May 25, 2004 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Salix Pharms XIFAXAN rifaximin TABLET;ORAL 022554-001 Mar 24, 2010 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,271,968

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,193,196 Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations ➤ Subscribe
8,518,949 Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations ➤ Subscribe
8,741,904 Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,271,968

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Ukraine 89809 ➤ Subscribe
Tunisia SN07292 ➤ Subscribe
Tunisia SN07250 ➤ Subscribe
Slovenia 1698630 ➤ Subscribe
Russian Federation 2397985 ➤ Subscribe
Russian Federation 2007136430 ➤ Subscribe
Serbia 54570 ➤ Subscribe
Serbia 20070364 ➤ Subscribe
Portugal 1698630 ➤ Subscribe
New Zealand 556737 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Harvard Business School
Medtronic
Cantor Fitzgerald
Teva
Farmers Insurance
UBS
Fuji
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot